Lian Brian 4
4 · Viking Therapeutics, Inc. · Filed Sep 20, 2024
Insider Transaction Report
Form 4
Lian Brian
DirectorPresident & CEO
Transactions
- Sale
Common Stock, par value $0.00001 per share
2024-09-20$71.15/sh−119,874$8,529,047→ 2,305,127 total - Exercise/Conversion
Common Stock, par value $0.00001 per share
2024-09-20$7.77/sh+166,130$1,290,830→ 2,521,057 total - Sale
Common Stock, par value $0.00001 per share
2024-09-20$70.43/sh−96,056$6,765,109→ 2,425,001 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-09-20−166,130→ 65,000 totalExercise: $7.77From: 2021-01-03Exp: 2030-01-03→ Common Stock (166,130 underlying) - Sale
Common Stock, par value $0.00001 per share
2024-09-20$71.98/sh−200$14,397→ 2,304,927 total
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule10b5-1 trading plan adopted on May 8, 2024 by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.90 to $70.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.90 to $71.89, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.97 to $72.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]25% of the shares subject to the option vested on each anniversary of the grant date.